HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.

AuthorsS J Kim, K Kim, B S Kim, C Suh, J Huh, Y H Ko, W S Kim
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 20 Issue 2 Pg. 390-2 (Feb 2009) ISSN: 1569-8041 [Electronic] England
PMID19211502 (Publication Type: Clinical Trial, Phase II, Letter, Multicenter Study)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Cytarabine
  • Alemtuzumab
  • Dexamethasone
  • Cisplatin
Topics
  • Adult
  • Alemtuzumab
  • Anemia (chemically induced)
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cisplatin (therapeutic use)
  • Cytarabine (therapeutic use)
  • Dexamethasone (therapeutic use)
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Humans
  • Leukopenia (chemically induced)
  • Longitudinal Studies
  • Lymphoma, T-Cell (drug therapy)
  • Lymphoma, T-Cell, Peripheral (drug therapy)
  • Male
  • Middle Aged
  • Prospective Studies
  • Recurrence
  • Salvage Therapy
  • Survival Analysis
  • T-Lymphocytes (drug effects)
  • Thrombocytopenia (chemically induced)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: